Preferences for oral and parenteral antitumor therapy: A survey of 260 patients with metastatic breast cancer

  title={Preferences for oral and parenteral antitumor therapy: A survey of 260 patients with metastatic breast cancer},
  author={M. Paley and N. Love and R. Carlson and D. Tripathy and R. Kaderman and D. Paley and J. Dvorkin and Kathryn A. Ziel},
  journal={Journal of Clinical Oncology},
619 Background: Oral, intravenous (IV), intramuscular (IM) and subcutaneous (SQ) therapies are commonly utilized to treat patients with metastatic breast cancer (PMBC), and often the risk-benefit ratios of these palliative options are similar. Two common clinical scenarios that offer choices for women with metastatic breast disease are: (1) The oral fluoropyrimidine prodrug, capecitabine or IV agents/ regimens, and (2) For postmenopausal women, daily oral endocrine agents, such as tamoxifen and… Expand
Effective oral chemotherapy for breast cancer: pillars of strength.
The wealth of data available and the increasing use of oral agents in breast cancer suggest that many of the concerns and perceptions about oral therapy, including efficacy and bioavailability, have been overcome, and that oral therapy will play a major role in Breast cancer management in the future in both the metastatic and adjuvant settings. Expand
Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer.
The recommended all oral capecitabine/cyclophosphamide combination regimen is well tolerated and active in MBC, and is being evaluated in a phase II study in anthracycline-pretreated MBC. Expand
Oral treatment of metastatic breast cancer with capecitabine: what influences the decision-making process?
It is suggested that most patients prefer oral chemotherapy because of the convenience and possibility of staying at home during treatment, and capecitabine provides a very effective treatment for MBC and additionally addresses patients' desire to receive treatment at home. Expand
Anticancer oral therapy: emerging related issues.
Current evidences show similar quality of life profile between oral and intravenous treatments, although anticancer oral therapy seems to be more convenient in terms of administration and reduced time lost for work or other activities. Expand
Capecitabine and vinorelbine in metastatic breast cancer.
The strongest clinical data support cape citabine monotherapy in the majority of patients, and in certain populations, a capecitabine-vinorelbine combination may be appropriate but requires further validation in randomised trials. Expand
Nursing perspectives on fulvestrant for the treatment of postmenopausal women with metastatic breast cancer.
Oncology nurses are provided with the knowledge needed to educate patients on the use of fulvestrant, to effectively administer this medication, and to prevent and manage potential side effects. Expand
A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II.
The difference in tumour response suggests a reasonable chance that CCy is superior to C alone, according to a multicentre, randomized, phase II study on capecitabine and cyclophosphamide in patients with locally advanced or metastatic breast cancer. Expand
Capecitabine and Oral Cyclophosphamide Combination in Taxane/Antrhracycline Resistant Metastatic Breast Cancer
Capecitabine and oral cyclophosphamide combination is a promising and well tolerated regimen in patients who previously had received taxanes and anthracyclines and in patients with cerbB2 positive tumors who received trastuzumab previously. Expand
Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents
Adherence and persistence to new oral biologic agents, which are linked to several side effects and whose use is constantly widening, should represent a main endpoint of clinical research in the nearest future. Expand
The patient experience
The major benefits of letrozole are to improve prospects for long-term survivorship in the adjuvant setting and to delay progression and the need for chemotherapy in the metastatic setting. Expand